Last $3.82 USD
Change Today -0.06 / -1.55%
Volume 18.6K
ROSG On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Open
$3.88
Previous Close
$3.88
Day High
$3.90
Day Low
$3.81
52 Week High
03/19/14 - $6.69
52 Week Low
11/20/13 - $2.35
Market Cap
37.5M
Average Volume 10 Days
72.1K
EPS TTM
--
Shares Outstanding
9.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; and a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

45 Employees
Last Reported Date: 03/31/14
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosetta genomics ltd (ROSG) Key Developments

Rosetta Genomics Ltd. Appoints Douglas Sites as Executive Vice President of Sales and Marketing

Rosetta Genomics Ltd. announced the appointment of Douglas Sites to the newly-created position of Executive Vice President of Sales and Marketing. Mr. Sites will report to Kenneth A. Berlin, Rosetta's President and Chief Executive Officer. Mr. Sites joins Rosetta Genomics with more than 25 years of experience in the sales and marketing of medical products, predominantly in diagnostics and laboratory services. Most recently he was Vice President of Sales and Marketing at Asuragen, a high-complexity CLIA laboratory with a focus on microRNA-based diagnostics as well as indeterminate thyroid diagnostics. Prior to Asuragen, Mr. Sites was Director of Sales-Hematology and Oncology at PLUS Diagnostics.

Rosetta Genomics Ltd. Signs an Agreement with Global Pharmaceutical Company

Rosetta Genomics Ltd. announced that it has signed an agreement with a global pharmaceutical company (GPC) in the area of Alzheimer's disease (AD) diagnostics. Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD. Rosetta will leverage the GPC's expertise in AD as it is considered a pioneer in the development and commercialization of therapeutics for AD.

Rosetta Genomics Announces Collaborative Research and License Agreement with Yeda Research and Development Company Ltd. for Personalized Medicine

Rosetta Genomics Ltd. announced that the company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science. The agreement involves collaboration with the Nancy and Stephen Grand Israel National Center for Personalized Medicine to develop novel methods for the preparation of next-generation sequencing libraries for small RNAs. The initial goals of this collaboration are to make this type of sequencing more cost effective as well as to minimize sequence-specific biases. The collaboration also aims at developing computational methods required for data analysis. The potential developed methods could allow more accurate quantification of microRNAs in various biological samples and pathological conditions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.82 USD -0.06

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $24.98 USD -0.07
Genomic Health Inc $27.96 USD -0.27
NeoGenomics Inc $5.25 USD +0.04
Response Genetics Inc $0.83 USD -0.0001
Veracyte Inc $12.72 USD +0.18
View Industry Companies
 

Industry Analysis

ROSG

Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.6x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit www.rosettagenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.